GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Naturewise Biotech & Medicals Corp (ROCO:4732) » Definitions » Return-on-Tangible-Asset

Naturewise Biotech & Medicals (ROCO:4732) Return-on-Tangible-Asset : 2.72% (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Naturewise Biotech & Medicals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Naturewise Biotech & Medicals's annualized Net Income for the quarter that ended in Jun. 2024 was NT$18.1 Mil. Naturewise Biotech & Medicals's average total tangible assets for the quarter that ended in Jun. 2024 was NT$663.8 Mil. Therefore, Naturewise Biotech & Medicals's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2024 was 2.72%.

The historical rank and industry rank for Naturewise Biotech & Medicals's Return-on-Tangible-Asset or its related term are showing as below:

ROCO:4732' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -20.75   Med: -2.26   Max: 11.3
Current: 2.4

During the past 13 years, Naturewise Biotech & Medicals's highest Return-on-Tangible-Asset was 11.30%. The lowest was -20.75%. And the median was -2.26%.

ROCO:4732's Return-on-Tangible-Asset is ranked better than
86.09% of 1503 companies
in the Biotechnology industry
Industry Median: -39.43 vs ROCO:4732: 2.40

Naturewise Biotech & Medicals Return-on-Tangible-Asset Historical Data

The historical data trend for Naturewise Biotech & Medicals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Naturewise Biotech & Medicals Return-on-Tangible-Asset Chart

Naturewise Biotech & Medicals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.97 11.30 4.88 4.59 1.54

Naturewise Biotech & Medicals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.26 3.79 1.05 2.06 2.72

Competitive Comparison of Naturewise Biotech & Medicals's Return-on-Tangible-Asset

For the Biotechnology subindustry, Naturewise Biotech & Medicals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Naturewise Biotech & Medicals's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Naturewise Biotech & Medicals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Naturewise Biotech & Medicals's Return-on-Tangible-Asset falls into.



Naturewise Biotech & Medicals Return-on-Tangible-Asset Calculation

Naturewise Biotech & Medicals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=10.12/( (650.084+661.066)/ 2 )
=10.12/655.575
=1.54 %

Naturewise Biotech & Medicals's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=18.062/( (661.066+666.467)/ 2 )
=18.062/663.7665
=2.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Jun. 2024) net income data.


Naturewise Biotech & Medicals  (ROCO:4732) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Naturewise Biotech & Medicals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Naturewise Biotech & Medicals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Naturewise Biotech & Medicals Business Description

Traded in Other Exchanges
N/A
Address
No. 36, Bade Road, 6th Floor, Section 3, Songshan District, Taipei, TWN, 105
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.

Naturewise Biotech & Medicals Headlines

No Headlines